Welcome to our dedicated page for Flora Growth SEC filings (Ticker: FLGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Flora Growth Corp navigates a patchwork of cannabis regulations can feel overwhelming when its 300-page annual report details everything from Colombian cultivation yields to European import permits. If you’ve ever wondered where to spot facility expansion costs or which insiders sold shares after a policy shift, this SEC filings hub solves that problem.
Stock Titan’s AI-powered analysis turns dense disclosures into clear talking points. Open a Flora Growth quarterly earnings report 10-Q filing and our summaries flag segment revenue swings in seconds. Need real-time alerts? You’ll receive Flora Growth Form 4 insider transactions real-time, so monitoring executive stock transactions Form 4 becomes a routine check, not a research project. Each document—whether an 8-K material events explained note on a new export license or a proxy statement executive compensation table—is linked, searchable, and translated into plain language.
Use this page to:
- Review a Flora Growth annual report 10-K simplified to understand cost-per-gram metrics and cultivation capacity.
- Follow Flora Growth insider trading Form 4 transactions to gauge management’s market sentiment.
- Dive into statutory updates with a Flora Growth 8-K material events explained summary.
- Compare margins quarter-over-quarter with Flora Growth earnings report filing analysis powered by AI.
Whether you’re a fund analyst, compliance professional, or individual investor, understanding Flora Growth SEC documents with AI means less time combing through footnotes and more time making informed decisions.
Flora Growth Corp. (NASDAQ: FLGC) – Form 4 insider transaction
Director Harold Wolkin reported a single set of transactions dated 30 June 2025 involving his previously granted 30,000 Stock Appreciation Rights (SARs). The filing shows a two-step modification approved by shareholders:
- Disposition (Code D): Cancellation of the original 30,000 SARs carrying a $1.30 exercise price.
- Acquisition (Code A): Issuance of an equal number of replacement SARs at a reduced exercise price of $0.58, maintaining the same 12 Dec 2034 expiration date.
The amendment effectively reprices the award to a level more in line with Flora Growth’s current market valuation, enhancing the economic value of the director’s incentive without changing the underlying share count. Following the adjustment, Mr. Wolkin continues to hold 30,000 SARs; no common shares were bought or sold, and no change occurred in his direct equity ownership.
Investor takeaways
- The repricing is shareholder-approved, indicating formal governance compliance.
- Total potential dilution is unchanged (still 30,000 shares), but the lower strike increases the likelihood that the award will be exercised, marginally raising dilution risk if the stock price recovers.
- The disclosure is routine and does not affect current revenue, earnings, or cash flow figures.
Flora Growth Corp. (FLGC) – Form 4 insider transaction
Director Manfred Leventhal reported changes to his derivative holdings on 30 June 2025. The filing concerns Stock Appreciation Rights (SARs) originally granted on 15 December 2024.
- 5,000 SARs with a US$1.30 exercise price were cancelled/disposed (code “D”).
- 5,000 replacement SARs were acquired (code “A”) with a reduced exercise price of US$0.58.
- The SARs retain the same exercisable start date (15 Dec 2024) and expiration date (15 Dec 2034).
- Post-transaction, Leventhal continues to hold 5,000 SARs directly; no change in the underlying number of common shares that could be issued.
- The company states that the repricing was approved by shareholders.
No non-derivative equity transactions were reported, and there is no indication of open-market buying or selling of common shares. The filing is therefore primarily administrative, reflecting the repricing of an existing equity incentive rather than an incremental ownership change.
On 1 July 2025, Flora Growth Corp. (FLGC) CFO Dany Vaiman filed a Form 4 disclosing the amendment of three previously granted Stock Appreciation Rights ("SARs") packages.
The original awards covering 907,161 SARs with exercise prices of $1.21, $0.915 and $1.30 were cancelled (Code D) on 30 Jun 2025 and immediately replaced by an identical number of SARs with a reduced exercise price of $0.58 (Code A). Shareholder approval for the repricing had been obtained.
The amended SARs retain their original expirations (15 Dec 2034 for 715,388 units and 14 Aug 2034 for 191,773 units) and vest in eight equal instalments, each contingent on specific share-price targets. After the transaction, Vaiman continues to hold 907,161 SARs; no common shares were bought or sold.
Although the filing has no immediate P&L or share-count impact, lowering the strike materially increases the likelihood that the options will finish in-the-money, potentially adding dilution and incremental compensation expense if FLGC’s share price appreciates.
On 1 July 2025, Flora Growth Corp. (FLGC) CFO Dany Vaiman filed a Form 4 disclosing the amendment of three previously granted Stock Appreciation Rights ("SARs") packages.
The original awards covering 907,161 SARs with exercise prices of $1.21, $0.915 and $1.30 were cancelled (Code D) on 30 Jun 2025 and immediately replaced by an identical number of SARs with a reduced exercise price of $0.58 (Code A). Shareholder approval for the repricing had been obtained.
The amended SARs retain their original expirations (15 Dec 2034 for 715,388 units and 14 Aug 2034 for 191,773 units) and vest in eight equal instalments, each contingent on specific share-price targets. After the transaction, Vaiman continues to hold 907,161 SARs; no common shares were bought or sold.
Although the filing has no immediate P&L or share-count impact, lowering the strike materially increases the likelihood that the options will finish in-the-money, potentially adding dilution and incremental compensation expense if FLGC’s share price appreciates.
Morgan Stanley Finance LLC, guaranteed by Morgan Stanley (NYSE: MS), is marketing “Worst-of RTY & SPX Callable Jump Notes” maturing 5 Aug 2030. The notes are linked to the Russell 2000 (RTY) and the S&P 500 (SPX) and offer 100 % participation in any positive performance of the worst-performing index, subject to the issuer’s right to call.
Early-redemption mechanism: starting 5 Aug 2026 and monthly thereafter (48 dates), the issuer will call the notes if a proprietary risk-neutral model indicates it is economic to do so. Investors receive a fixed “jump” payment that begins at $1,120 (12 % over par) and rises by $10 every month to $1,590 (59 % over par) by July 2030.
At maturity (if never called) investors receive: • par plus 100 % upside on the worst performer, capped only by the 59 % maximum shown in the hypothetical table; • full principal protection—even if either index falls 100 %, payment is still $1,000. The notes pay no periodic coupons.
Key economics: issue price $1,000; estimated value $961.40 (approximately 3.9 % below par, reflecting structuring and hedging costs). CUSIP 61778NDQ1. The securities will not be exchange-listed; liquidity will depend on Morgan Stanley’s secondary market.
Principal risks detailed in the FWP include: call risk (upside cut off), no interest income, credit risk of Morgan Stanley, small-cap exposure via RTY, and potential adverse pricing in secondary trading. Investors should consult the full preliminary pricing supplement and tax discussion before investing.
FAQ
What is the current stock price of Flora Growth (FLGC)?
What is the market cap of Flora Growth (FLGC)?
What are the core business segments of Flora Growth Corp?
How does Flora Growth Corp maintain quality and regulatory compliance?
What distinguishes Flora Growth Corp in the competitive cannabis market?
Which markets does Flora Growth Corp primarily serve?
How does Flora Growth Corp address supply chain challenges?
What types of products does Flora produce?
How important are strategic partnerships to Flora Growth Corp?
Is Flora Growth Corp focused on innovation in its industry?
